• Hydreight Technologies disclosed a C$ 300,000 minority investment in Insu Therapeutics, completed on March 13, 2026.
• The deal also granted Hydreight U.S. distribution rights for peptide medicines using Insu’s buccal delivery technology, subject to development success.
• Insu received a USPTO Notice of Allowance on a buccal peptide-delivery patent application, reinforcing Hydreight’s strategic stake.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hydreight Technologies Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202610080730CANADANWCANADAPR_C0229) on October 08, 2026, and is solely responsible for the information contained therein.